Home > PE Ratio > ORCHID PHARMA

ORCHID PHARMA
PE (Price/Earnings) Ratio

The Current P/E Ratio of ORCHID PHARMA is 42.45.

Share Price ₹1,062.7Apr 24,2024
Market Cap ₹5,387.9 Cr
Earnings-TTM₹126.9 CrTTM-Consolidated Results
Price/Earnings42.45xCalculated as Market Cap/Earnings
Explore Stock Analytics
COMMUNITY POLL
for ORCHID PHARMA
Please provide your vote to see the results
ORCHID PHARMA is part of below Screeners ↓
Best Quarterly Growth Small Cap Stocks

Definition & Calculation of PE (Price/Earnings) ratio of ORCHID PHARMA

Price-to-Earnings ratio, P/E Multiple, or P/E Ratio is an important valuation multiple that is defined as:

P/E = Market Capitalization / Net Income

or, using per-share numbers:

P/E = Stock Price / Earnings Per Share (EPS)

Applying the above formula, P/E ratio of ORCHID PHARMA is calculated as :

Current Market Cap [ ₹5,387.9 Cr] as on Apr 24,2024

(/) Earnings [ ₹126.9 Cr] based on TTM-Consolidated Results

(=) P/E Ratio [ 42.45x ]

P/E Ratio indicates the multiple of earnings investors are willing to pay to own one share of the company.

Thus, for ORCHID PHARMA , the investors are currently willing to pay 42.45 times earnings to own 1 share of the company.

PE Multiples are the most widely used valuation multiple in practice.

Since P/E ratio uses Net Income in the calculation, P/E multiples are not always reliable for valuing companies with negative earnings.

In such cases, you may consider using Price to Book ratio or Price to Sales ratio of ORCHID PHARMA !

P/E ratios, also, would not adjust for differences in the capital structure between companies.

The chart below summarizes the trend in P/E Ratio of ORCHID PHARMA over the last five years.

Historical PE (Price/Earnings) ratio chart of ORCHID PHARMA


PE Ratio Performance Analysis for ORCHID PHARMA

- ORCHID PHARMA 's latest p/e ratio is 42.45x.

- ORCHID PHARMA 's p/e ratio for fiscal years ending Mar2023 to Mar2019 averaged 6.91x.

- ORCHID PHARMA 's operated at median p/e ratio of 0x from fiscal years ending March 2018 to 2022.

- Looking back at the last 5 fiscal years, ORCHID PHARMA 's p/e ratio peaked in Mar2023 at 33.87x.

- ORCHID PHARMA 's p/e ratio hit its five-year low in Mar2022 of 0x.


How does ORCHID PHARMA 's P/E Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?

Peer Comparison (Pharmaceuticals & Drugs Industry)Earnings-TTM (Cr)PE RatioMarket Cap
ORCHID PHARMA 126.9242.455,387.9
SUN PHARMACEUTICAL INDUSTRIES LTD8,998.6339.63356,625.0
CIPLA LTD3,744.0330.16112,938.0
DR REDDYS LABORATORIES LTD5,209.4019.0699,276.9
ZYDUS LIFESCIENCES LTD2,954.2031.7993,921.9
DIVIS LABORATORIES LTD1,382.9773.26101,315.0
MANKIND PHARMA LTD1,743.3055.1596,143.2
TORRENT PHARMACEUTICALS LTD1,494.0060.8390,872.6
LUPIN LTD1,809.7439.7972,010.8
AUROBINDO PHARMA LTD2,777.8922.8663,492.3
ABBOTT INDIA LTD1,145.5847.2354,105.4

Pharmaceuticals & Drugs Industry Benchmark (Top 10) PE Analysis vs ORCHID PHARMA 's P/E Ratio

Top 10 Industry PeersPE Ratio
Min industry PE 19.06x
Max industry PE 73.26x
Median industry PE 39.79x
Average industry PE 42.02x



You may also like the below Video Courses